Chao Kuang Piu High-tech Development Fund

Questis Named Best Startup by HackerNoon & The Tech Tribune

Retrieved on: 
Friday, April 22, 2022
St. Louis Fed Financial Stress Index, Growth, Motivation, Investment, CEO, Chao Kuang Piu High-tech Development Fund, Technology, Giulio Questi, Multimedia, Industry, Entrepreneurship, Publication, Workforce, Pharmaceutical industry, Management

CHARLESTON, S.C., April 21, 2022 /PRNewswire/ -- Charleston-based workforce financial empowerment company Questis has been named 'Best Startup' by tech development outlets HackerNoon & The Tech Tribune. Questis was selected from a strong pool of innovative tech startups nominated for the award at both publications.

Key Points: 
  • CHARLESTON, S.C., April 21, 2022 /PRNewswire/ --Charleston-based workforce financial empowerment company Questis has been named 'Best Startup' by tech development outlets HackerNoon & The Tech Tribune .
  • Questis was selected from a strong pool of innovative tech startups nominated for the award at both publications.
  • "It's a great honor to receive these awards from two leading tech outlets," said John Tabb, Co-Founder and CEO .
  • The Questis platform is an all-in-one financial benefit solution powered by data-driven technology to provide personalized and prescriptive financial coaching.

Bruker Announces Collaborative Advances in CCS-Enabled 4D Proteomics Workflows at HUPO

Retrieved on: 
Tuesday, November 16, 2021
Health, Stem Cells, Research, Pharmaceutical, Science, Biotechnology, Adoption, Litre, SCP, Biomarker, Secondary research, Plasma, Seer, Tissue, HUPO, Founder, Ist, CEO, Congress, Disease, Technology, CCS, Proteomics, Multimedia, Cell biology, Research, Proteome, IDS, Partnership, Workflow, Acquisition, Protein, Chao Kuang Piu High-tech Development Fund, Solution, Isolate, Microscopy, Nasdaq, Beatbox, Life, 3D printing, Fine chemical, Feed manufacturing

At the virtual 20th Human Proteome Organization World Congress, HUPO Reconnect 2021 ( hupo2021.org ) Bruker Corporation (Nasdaq: BRKR) announced major advances in collision cross section (CCS) enabled 4D proteomics workflows on the unique timsTOF multiomics platform.

Key Points: 
  • At the virtual 20th Human Proteome Organization World Congress, HUPO Reconnect 2021 ( hupo2021.org ) Bruker Corporation (Nasdaq: BRKR) announced major advances in collision cross section (CCS) enabled 4D proteomics workflows on the unique timsTOF multiomics platform.
  • We are excited to announce that Bruker is collaborating with industry-leading partners on higher performance, automated workflows in three key areas: single-cell proteomics, plasma proteomics and tissue proteomics.
  • Bruker announces a co-marketing agreement with Cellenion on the cellenONE single-cell isolation and nanoliter dispensing robotic platform.
  • The partnership with Cellenion on label-free 4D single-cell proteomics (SCP) provides timsTOF SCP users with an end-to-end solution.

Delfi Bolsters Leadership Team with Three Key Hires

Retrieved on: 
Thursday, October 21, 2021
People, Diagnosis, Fforestfach, MD, Research, Technology, Cancer, Goal, Organization, Software engineering, Adaptation, Algorithm, Patient, Founder, Adoption, Machine learning, Tobias, McDaniel, Time, VP, Life, Translational Genomics Research Institute, GRAIL, Senior, Chao Kuang Piu High-tech Development Fund, Multimedia, Delfi, DNA, Acquisition, Exact sciences, Deloitte, Doctor of Philosophy, International development, Management, Fine chemical, Medical imaging

"One of the main reasons I'm excited about leading technology development at Delfi is the simplicity of the assay -- it's inherently scalable and cost-effective," said McDaniel. "Making this technology ready for wide-scale implementation means more patients will be able to take action against their cancer as early as possible."

Key Points: 
  • "As Delfi continues to grow, it is of critical importance to have a diverse and talented leadership team with the right experience and capabilities to ensure we're meeting all of our most important goals," said Victor Velculescu, MD, PhD, Delfi Diagnostics CEO and Founder.
  • "The additions of Tim, Mo, and Tobias will be invaluable in helping to move Delfi forward."
  • Prior to TGen, he led programs at Illumina to develop the company's core next-generation sequencing reagents and other consumables.
  • Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.